StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$33.38+0.40 (+1.21%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%

Castle Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Castle Biosciences's revenue for the twelve months ending Sep 30, 2026 was $377.13M, up 9.8% year over year. For fiscal 2025 it was $344.23M, up 3.7% from the year before. The highest annual figure on record is $344.23M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$344.23M+3.7%
FY2024Dec 31, 2024$332.07M+51.1%
FY2023Dec 31, 2023$219.79M+60.4%
FY2022Dec 31, 2022$137.04M+45.7%
FY2021Dec 31, 2021$94.09M+50.2%
FY2020Dec 31, 2020$62.65M+20.8%
FY2019Dec 31, 2019$51.87M+127.6%
FY2018Dec 31, 2018$22.79M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$102.89M+23.9%
Q2 FY2026Jun 30, 2026$103.55M+20.1%
Q1 FY2026Mar 31, 2026$83.68M-4.9%
Q4 FY2025Dec 31, 2025$87.01M+0.8%
Q3 FY2025Sep 30, 2025$83.04M-3.2%
Q2 FY2025Jun 30, 2025$86.19M-0.9%
Q1 FY2025Mar 31, 2025$87.99M+20.6%
Q4 FY2024Dec 31, 2024$86.31M+30.5%
Q3 FY2024Sep 30, 2024$85.78M+39.5%
Q2 FY2024Jun 30, 2024$87.00M+73.5%
Q1 FY2024Mar 31, 2024$72.97M+73.6%
Q4 FY2023Dec 31, 2023$66.12M+72.5%
Q3 FY2023Sep 30, 2023$61.49M+66.1%
Q2 FY2023Jun 30, 2023$50.14M+43.9%
Q1 FY2023Mar 31, 2023$42.04M+56.6%
Q4 FY2022Dec 31, 2022$38.34M+53.1%
Q3 FY2022Sep 30, 2022$37.01M+57.7%
Q2 FY2022Jun 30, 2022$34.84M+53.1%
Q1 FY2022Mar 31, 2022$26.85M+17.7%
Q4 FY2021Dec 31, 2021$25.04M+44.7%
Q3 FY2021Sep 30, 2021$23.48M+54.3%
Q2 FY2021Jun 30, 2021$22.76M+79.0%
Q1 FY2021Mar 31, 2021$22.81M+31.0%
Q4 FY2020Dec 31, 2020$17.30M-1.9%
Q3 FY2020Sep 30, 2020$15.22M+3.0%
Q2 FY2020Jun 30, 2020$12.72M+18.4%
Q1 FY2020Mar 31, 2020$17.42M+99.8%
Q4 FY2019Dec 31, 2019$17.64M+54.2%
Q3 FY2019Sep 30, 2019$14.77M+298.0%
Q2 FY2019Jun 30, 2019$10.74M+169.9%
Q1 FY2019Mar 31, 2019$8.72M+138.2%
Q4 FY2018Dec 31, 2018$11.44M–
Q3 FY2018Sep 30, 2018$3.71M–
Q2 FY2018Jun 30, 2018$3.98M–
Q1 FY2018Mar 31, 2018$3.66M–

More Castle Biosciences figures

See a number that looks wrong?